Drilldown/Medicines

Asenapine (1) · Butorphanol (1) · Chlorpromazine (1) · Codeine (2) · Dextropropoxyphene (1) · Dihydrocodeine (1) · Droperidol (1) · Estradiol (17β-estradiol) (1) · Ethylmorphine (1) · Fentanyl (1) · Fluphenazine (1) · Hydrocodone (1) · Hydromorphone (1) · Iloperidone (1) · Levorphanol (1) · Loxapine (1) · Lurasidone (1) · Meperidine (1) · Molindone (1) · Nalbuphine (1) · Oxymorphone (1) · Paliperidone (1) · Papaverine (1) · Pentazocine (1) · Perphenazine (1) · Pimozide (1) · Progesterone (micronized) (1) · Tapentadol (1) · Thioridazine (1) · Thiothixene (1) · Trifluoperazine (1) · Ziprasidone (1)

None (5) · (multiple, generic dominant) (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Duragesic (1) · Estrace, Vivelle-Dot, Climara, Divigel, Evamist, Estring, Estraderm, Premarin (CEE, not strictly estradiol) (1) · Fanapt (1) · Geodon (1) · Inapsine (1) · Invega (1) · Latuda (1) · Loxitane (1) · Mellaril (1) · Moban (1) · Navane (1) · Nubain (1) · Nucynta (1) · Opana (1) · Orap (1) · Prolixin (1) · Prometrium (oral), Endometrin (vaginal), Crinone (vaginal gel), Prochieve (1) · Saphris (1) · Stadol (1) · Stelazine (1) · Talwin (1) · Thorazine (1) · Trilafon (1) · Vicodin (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

None (2) · Butyrophenone D2 antagonist (1) · D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) · D2/5-HT2A antagonist (1) · D2/5-HT2A antagonist; 5-HT7 antagonist (1) · D2/5-HT2A antagonist; active metabolite of risperidone (1) · D2/5-HT2A antagonist; SRI and NRI (1) · Dibenzoxazepine D2/5-HT2 antagonist (1) · Dihydroindolone D2 antagonist (1) · Diphenylbutylpiperidine D2 antagonist (1) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) · Phenothiazine D2 antagonist (4) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (3) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Thioxanthene D2 antagonist (1)

None (30) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-000003B5-QINU`"', '"`UNIQ--vote-000003B6-QINU`"', '"`UNIQ--vote-000003B7-QINU`"', '"`UNIQ--vote-000003B8-QINU`"', '"`UNIQ--vote-000003B9-QINU`"' (1) · '"`UNIQ--vote-00000722-QINU`"', '"`UNIQ--vote-00000723-QINU`"', '"`UNIQ--vote-00000724-QINU`"', '"`UNIQ--vote-00000725-QINU`"' (1)

None (30) · Adult: 15–60 mg every 4 hours as needed. (1) · HRT cyclic: 200 mg PO HS days 1-12 of each month; continuous: 100 mg PO daily; ART luteal support 100 mg vaginal TID or 90 mg gel daily (1) · Oral 1-2 mg daily; transdermal patch 0.025-0.05 mg/d twice weekly; transdermal gel 0.5-1 g/d; vaginal 10 mcg tablet twice weekly for GSM. Always combine with a progestogen in patients with an intact uterus. (1)

None (30) · Oral 0.5, 1, 2 mg tablets; transdermal patches (twice-weekly and once-weekly); 0.06% gel; 1.53 mg/spray topical; vaginal ring (Estring); vaginal tablet (Vagifem/Yuvafem); vaginal cream (1) · Oral 100, 200 mg capsules (peanut oil; check allergy); 100 mg vaginal insert (Endometrin); 4%, 8% vaginal gel (Crinone); IM 50 mg/mL (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (30) · 360 mg/day (1) · Indication-dependent; 200-400 mg/d oral typical (1) · Indication-specific; lowest effective dose for shortest duration is the WHI-era standard (1)

None (30) · cypionate) (1) · IM (estradiol valerate (1) · intramuscular (1) · Oral (2) · PO (only formulation marketed in the US). (1) · transdermal (1) · vaginal (2)

None (30) · 30–60 min (PO) (1) · Sedation/dizziness within hours of oral dose; endometrial effects over days (1) · Vasomotor relief 2-4 weeks; bone density gains over months (1)

None (30) · 4–6 hours (1) · Oral: 8-12 hours; vaginal: 24+ hours; IM: days (1) · Route- and formulation-dependent (1)

None (30) · 2.5–3 hours (1) · ~13-20 hours (oral); transdermal pharmacokinetics buffer the peaks/troughs of oral dosing'"`UNIQ--ref-000003BA-QINU`"' (1) · ~5-20 hours (oral micronized; highly variable)'"`UNIQ--ref-00000726-QINU`"' (1)

None (30) · Oral ~5% (extensive first-pass to estrone and conjugates); transdermal bypasses first-pass, giving more physiologic estradiol:estrone ratio'"`UNIQ--ref-000003BB-QINU`"' (1) · Oral: very low (extensive first-pass); micronization improves uptake somewhat. Vaginal: high local effect with lower systemic levels (first-uterine-pass concentration)'"`UNIQ--ref-00000727-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (31) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Contraindicated in pregnancy (use is not appropriate during gestation; class label X). Lactation considerations vary by indication.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (30) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (2)